Clinical Efficacy of Transcatheter Arterial Chemoembolization Combined With Percutaneous Microwave Coagulation Therapy for Advanced Hepatocellular Carcinoma.

IF 1.4 Q4 GASTROENTEROLOGY & HEPATOLOGY

Gastroenterology Research Pub Date : 2024-08-01 Epub Date: 2024-07-18 DOI:10.14740/gr1713

Hu Hu Ren, Zhi Qun Wu, Jian Chen, Chen Li

{"title":"Clinical Efficacy of Transcatheter Arterial Chemoembolization Combined With Percutaneous Microwave Coagulation Therapy for Advanced Hepatocellular Carcinoma.","authors":"Hu Hu Ren, Zhi Qun Wu, Jian Chen, Chen Li","doi":"10.14740/gr1713","DOIUrl":null,"url":null,"abstract":"Background: The aim of the study was to explore the clinical efficacy of transcatheter arterial chemoembolization (TACE) combined with percutaneous microwave coagulation therapy (PMCT) for advanced hepatocellular carcinoma (HCC).Methods: Eighty-three advanced HCC patients were divided into the experimental group (TACE + PMCT, 57 cases) and the control group (TACE alone, 26 cases). They received TACE treatment first, and computed tomography (CT) or hepatic artery angiography was performed 3 - 4 weeks after each treatment. Based on the comprehensive evaluation of iodine oil deficiency, fistula recanalization, residual lesions, and lesion progression, TACE or PMCT treatment was selectively performed, and three consecutive treatments were considered as one treatment cycle.Results: The experimental group had a response rate (RR) of 49.1%, and the control group had a RR of 38.4%. The reduction rate of alpha-fetoprotein (AFP) in the experimental group was significantly higher than the control group (P < 0.05). The cumulative survival rates in the experimental at 1-, 1.5-, and 2-year post-treatment were higher than the control group. The cumulative recurrence and metastasis rates in the experimental at 1.5-, and 2-year post-treatment were significantly lower than those in the control group (P < 0.05). In addition, there were no significant differences in treatment-related complications in the two groups.Conclusions: The combined treatment of TACE and PMCT for advanced HCC is a safe, feasible, and effective treatment method, prolonging the survival time, and reducing the recurrence and metastasis rate, without increased toxic and side effects.","PeriodicalId":12461,"journal":{"name":"Gastroenterology Research","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11379045/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterology Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14740/gr1713","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/18 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The aim of the study was to explore the clinical efficacy of transcatheter arterial chemoembolization (TACE) combined with percutaneous microwave coagulation therapy (PMCT) for advanced hepatocellular carcinoma (HCC).

Methods: Eighty-three advanced HCC patients were divided into the experimental group (TACE + PMCT, 57 cases) and the control group (TACE alone, 26 cases). They received TACE treatment first, and computed tomography (CT) or hepatic artery angiography was performed 3 - 4 weeks after each treatment. Based on the comprehensive evaluation of iodine oil deficiency, fistula recanalization, residual lesions, and lesion progression, TACE or PMCT treatment was selectively performed, and three consecutive treatments were considered as one treatment cycle.

Results: The experimental group had a response rate (RR) of 49.1%, and the control group had a RR of 38.4%. The reduction rate of alpha-fetoprotein (AFP) in the experimental group was significantly higher than the control group (P < 0.05). The cumulative survival rates in the experimental at 1-, 1.5-, and 2-year post-treatment were higher than the control group. The cumulative recurrence and metastasis rates in the experimental at 1.5-, and 2-year post-treatment were significantly lower than those in the control group (P < 0.05). In addition, there were no significant differences in treatment-related complications in the two groups.

Conclusions: The combined treatment of TACE and PMCT for advanced HCC is a safe, feasible, and effective treatment method, prolonging the survival time, and reducing the recurrence and metastasis rate, without increased toxic and side effects.

查看原文本刊更多论文

经导管动脉化疗栓塞联合经皮微波凝固疗法治疗晚期肝细胞癌的临床疗效

研究背景该研究旨在探讨经导管动脉化疗栓塞术（TACE）联合经皮微波凝固疗法（PMCT）治疗晚期肝细胞癌（HCC）的临床疗效：83例晚期HCC患者被分为实验组（TACE + PMCT，57例）和对照组（单纯TACE，26例）。他们首先接受 TACE 治疗，每次治疗后 3-4 周进行计算机断层扫描（CT）或肝动脉造影。根据碘油缺乏、瘘管再通、残余病灶、病灶进展等综合评估结果，有选择性地进行TACE或PMCT治疗，连续三次治疗视为一个治疗周期：实验组反应率（RR）为 49.1%，对照组反应率为 38.4%。实验组甲胎蛋白（AFP）下降率明显高于对照组（P < 0.05）。实验组在治疗后 1 年、1.5 年和 2 年的累积生存率均高于对照组。实验组治疗后 1.5 年和 2 年的累积复发率和转移率明显低于对照组（P < 0.05）。此外，两组在治疗相关并发症方面无明显差异：结论：TACE和PMCT联合治疗晚期HCC是一种安全、可行、有效的治疗方法，可延长患者生存时间，降低复发率和转移率，且不会增加毒副作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gastroenterology Research GASTROENTEROLOGY & HEPATOLOGY-

自引率

0.00%

发文量